Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 14/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PGA5 | P0DJD9 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140056 | 1.00 | CA2 (0.44) | CA2RENCTSLKLKB1BACE1 | |
| SCHEMBL3140061 | 1.00 | CA2 (0.44) | CA2RENCTSLKLKB1BACE1 | |
| SCHEMBL1434219 | 0.88 | KLKB1 (0.42) | KLKB1 | |
| SCHEMBL1433934 | 0.85 | KLKB1 (0.39) | RENCTSLKLKB1 | |
| SCHEMBL1433933 | 0.85 | KLKB1 (0.39) | RENCTSLKLKB1 | |
| SCHEMBL1433938 | 0.85 | KLKB1 (0.39) | RENCTSLKLKB1 | |
| SCHEMBL1432454 | 0.85 | KLKB1 (0.40) | KLKB1 | |
| Trifluoroacetic Acid SCHEMBL1432772 | 0.84 | PSMB5 (0.43) | KLKB1 | |
| SCHEMBL1431768 | 0.84 | KLKB1 (0.43) | KLKB1 | |
| SCHEMBL1431611 | 0.84 | KLKB1 (0.40) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CA2 897/4885REN 1899/4885CTSL 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.